In solid oral dosage manufacture, riboflavin 98% pharma grade API is introduced as a low-dose active component, typically 1.7 mg to 10 mg per tablet, into high-shear wet granulation or direct compression process streams. The needle-shaped crystal habit and bulk density below 0.45 g/mL create flow resistance through rotary tablet press feed frames fitted with 10 mm diameter feed screws; a 20–30 mesh sieve is placed before the feed frame to reject agglomerates larger than 850 µm. A geometric dilution sequence with microcrystalline cellulose and lactose monohydrate is used to achieve an acceptance value not exceeding 15 under USP <905> for tablets containing less than 5 mg of riboflavin per unit. Dry blending in a 100 L bin blender at 10 rpm for 15–20 min produces an assay relative standard deviation below 4% only when the API is pre-disintegrated or granulated; untreated API with D90 above 120 µm generally yields higher RSD. Wet granulation with 5% w/w povidone K30 binder solution in a 25 L top-driven high-shear mixer at impeller speed 200 rpm and chopper speed 1500 rpm compacts riboflavin into granules with loss on drying 1.5–2.0% after fluid-bed drying with 50 °C inlet air. Magnesium stearate added at 0.5% w/w before final blending must remain under 5 min at 10 rpm to avoid over-lubrication and reduced tablet hardness. Tableting is performed on a 27-station rotary press with D-tooling, compression force 10–20 kN, target hardness 60–100 N and friability below 1.0% under USP <1216>. Uncoated riboflavin-containing tablets are transferred to opaque HDPE containers or coated with an aqueous light-blocking polymer; otherwise, photolysis under 450 nm illumination lowers assay below compendial limits. Batch release and documentation follow ICH Q7 and 21 CFR Part 210/211 good manufacturing requirements.

What limits dosator-type capsule fill variability for riboflavin blends?

Dosator-type capsule fillers operating at 30 cycles/min with size 0 hard gelatin capsules exhibit fill weight RSD above 5% when the riboflavin-containing blend shows a Hausner ratio greater than 1.35. Riboflavin powder with tapped density 0.45–0.65 g/mL and Carr index 25–35% requires pre-compaction or addition of 1.0% w/w colloidal silicon dioxide and 25% w/w pregelatinized starch to stabilize dosator pellet formation. Tamping pins set at 0.5 mm penetration depth are increased to 1.2 mm when the fill target exceeds 400 mg; powder bed height in the hopper is maintained at 60–80% of the total sensor range to avoid segregation. HPMC capsules used for moisture-sensitive formulations require environmental control at 35–45% RH and 18–22 °C, because riboflavin adsorbed onto hygroscopic vehicles can undergo photo-accelerated oxidation. Capsule disintegration is monitored under USP <701>, and dissolution is assessed using USP <711> apparatus 2. Low-dose riboflavin in capsule blends requires slugging or roller compaction before encapsulation when API content is below 1.0% to prevent segregation during machine vibration.

For granule and dry syrup presentations, riboflavin 98% pharma grade API is sieved through a 100-mesh screen; particle-size reduction to D90 ≤ 60 µm is specified to prevent needle-shaped crystals from puncturing low-density polyethylene sachet film and to reduce sedimentation after reconstitution. The API is granulated in a fluid-bed top-spray system with an aqueous binder solution of 10% w/w maltodextrin and 2% w/w povidone K30; granules are dried to loss on drying 2.0–2.5%, bulk density 0.55–0.70 g/mL, and median particle size 250–500 µm. Unit-dose sachet filling uses vertical form-fill-seal equipment with an auger filler; fill weight 2.0 g is held within ±4.0%. In reconstituted suspension at pH 5.0–5.5, riboflavin aqueous solubility remains below 0.1 mg/mL; therefore, the suspended solid fraction must be uniformly dispersed with xanthan gum 0.2% w/w and microcrystalline cellulose/carboxymethylcellulose sodium 1.0% w/w. Light exposure during storage of the reconstituted suspension in amber glass bottles reduces photodegradation; without amber packaging, lumiflavine formation under near-UV radiation can exceed compendial impurity limits within 8 hours. Because riboflavin has an intensely bitter taste, formulations above 5 mg per dose frequently require bitter-blocking agents or Wurster coating of granules with ethylcellulose at product temperature 30–35 °C; the coating also reduces yellow staining of the oral mucosa.

When riboflavin base is specified for injectable compounding

Aqueous injectable compounding of riboflavin 98% base encounters a solubility limit of approximately 0.1 mg/mL at 25 °C, which makes direct dissolution for a 5 mg/mL small-volume parenteral solution not feasible. The regulatory-compliant route typically uses riboflavin 5′-phosphate sodium dihydrate, which has a reported aqueous solubility above 50 mg/mL. When the parent base is selected as an intermediate, the phosphate ester is synthesized first, then lyophilized or filled as a nitrogen-sparged solution. Multi-ingredient injectable formulations sometimes employ nicotinamide as a hydrotropic solubilizer; published data for the exact solubility multiple in this specific composition are limited. Aseptic filling stations with 0.22 µm PES or PVDF membrane filters must shield the product from blue and near-UV light during the filling line to avoid photochemical generation of lumiflavine and lumichrome; in-line UV/Visible absorbance at 373 nm is used as a process analytical technology check. Terminal sterilization is not applied to heat-labile riboflavin phosphate solutions; aseptic processing under ISO 14644-1 class 5, USP <797>, and particulate control under USP <788> is required. Precipitation after pH adjustment above 7.0 or exposure to trace copper and iron above 0.2 µg/mL reduces filterability and chemical stability; therefore, rubber stopper contact surfaces are selected from chlorobutyl formulations without high metal extractables. Direct use of riboflavin base in aqueous injectable products is limited; without derivatization, only very low-strength or non-aqueous formulations can be considered, and full compendial validation for impurity profile remains mandatory.

Because riboflavin photolysis in total parenteral nutrition is accelerated by copper and iron at concentrations above 0.2 µg/mL, compounding operations for riboflavin-containing multi-trace element admixtures require conversion to light-protective amber PVC or EVA bags immediately after aseptic mixing. Admixture pH is maintained at 5.0–5.5 with citric acid buffer; under high-intensity ambient fluorescent lighting, pharmacists are instructed to use immediate light protection and infusion within 4–6 hours after compounding. Photo-bleaching of the yellow color is used as a visual process indicator; absence of yellow color after 4 hours indicates loss of riboflavin. In neonatal and pediatric parenteral nutrition, the daily riboflavin dose is often below 1 mg, requiring gravimetric dilution via a licensed multivitamin lyophilized preparation rather than direct weighing of the 98% base. Because light transmission through lipid emulsions differs from aqueous-only admixtures, time-resolved degradation in lipid-containing bags cannot be extrapolated from aqueous studies; published data for this specific configuration are limited. Infusion sets are shielded with amber or yellow light-protective foils during administration, and trace element admixtures are compounded separately from lipid emulsions to reduce photochemical and oxidative stress.

Film-coated B-complex tablets and light-blocking substrate requirements

In multi-drug B-complex tablet manufacture, riboflavin 98% API is incorporated into the granulation at a nominal assay of 1.5–2.5 mg per core, then coated with an aqueous light-blocking film containing titanium dioxide 2.0–3.0 mg/cm² and iron oxide pigment. The coating pan is operated at pan speed 4–8 rpm, spray rate 8–12 g/min per bed, inlet air temperature 55–65 °C, and exhaust air humidity 8–12 g/kg dry air. These parameters maintain bed temperature at 40–45 °C while avoiding over-wetting, which would mobilize riboflavin to the core surface and cause yellow mottling. Coated tablets are light-stressed in a photostability chamber under ICH Q1B option 2 conditions; packaging is accepted only when assay loss after light exposure does not exceed 5% and when individual lumiflavine-related impurities remain within the monograph limit. Because titanium dioxide opacity depends on film thickness uniformity, the coating endpoint is monitored by near-infrared reflectance rather than weight gain alone; a weight gain of 3.0–4.0% w/w is typical for a 250 mg core. Tablets packed in PVC/PVDC blisters without light-protective aluminum foil can show marginal photoprotection for riboflavin at high humidity; therefore, all primary packaging is qualified by photostability testing and not only by water-vapour transmission rate. The final blend also contains thiamine, pyridoxine, and cyanocobalamin; riboflavin interacts with these vitamins under moist heat, so dryer discharge moisture is controlled to below 2.5% and compression room humidity at 40–50% RH.